Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Board Member, VP at Biomatrica


Biomatrica said this week that Nicolas Barthelemy has been added to the company's board of directors while Jeff Whitmore has joined the company as vice president of commercial development.

Barthelemy most recently served at Life Technologies, including as chief commercial officer (president, global commercial operations), president of the cell systems division, senior VP of the cell culture systems division, and senior VP of global operations. Prior to his time at Life Technologies, he held several senior management positions at Biogen Idec. He holds an MS in chemical engineering from the University of California, Berkeley, and an engineering degree from École Supérieure de Physiques et Chimie Industrielles in Paris.

Whitmore joins Biomatrica from Singulex, where he was vice president of life science sales. He also served as vice president of imaging sales at ProteinSimple; executive vice president of global sales at Alpha Innotech; and director of European life science sales at Molecular Devices.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.